| Prev Close: | 21.04 |
|---|---|
| Open: | N/A |
| Bid: | 19.91 x 400 |
| Ask: | 21.44 x 400 |
| 1y Target Est: | 24.25 |
| Beta: | 1.28 |
| Next Earnings Date: | 29-Jul-13 |
| Day's Range: | N/A - N/A |
|---|---|
| 52wk Range: | 17.13 - 23.96 |
| Volume: | 0 |
| Avg Vol (3m): | 2,699,790 |
| Market Cap: | 5.67B |
| P/E (ttm): | N/A |
| EPS (ttm): | -0.39 |
| Div & Yield: | N/A (N/A) |
Quotes delayed, except where indicated otherwise. Currency in USD.
Headlines
- FDA Raises Concerns About The Cybersecurity Of Medical Devicesat Forbes(Tue, Jun 18)
- Why This Health Care Play Looks Like a Good Valueat Motley Fool(Fri, Jun 14)
- Quest Diagnostics To Offer Cancer Tests Following Supreme Court Gene Rulingat Barrons.com(Thu, Jun 13)
- [$$] Quest/Hologic Pact Squeezes Qiagenat Barrons.com(Mon, Jun 10)
- Quest and Hologic Extend TiesZacks(Fri, Jun 7)
- QIAGEN affirms FY13 view after Quest Diagnostics, Hologic strike dealat theflyonthewall.com(Thu, Jun 6)
- Midday Movers: LEN, KBH, PHM & Moreat CNBC(Thu, Jun 6)
- Quest Diagnostics and Hologic Form Strategic Alliance to Improve Women's HealthPR Newswire(Thu, Jun 6)
- Two-For-One: Cramer's Takeover & Break-Up Playat CNBC(Mon, Jun 3)
- The Zacks Analyst Blog Highlights: PowerShares DB US Dollar Index Bullish, CurrencyShares Japanese Yen Trust, CurrencyShares Euro Trust, CurrencyShares British Pound Ster. Trst and HologicZacks(Thu, May 30)
- Good News for HOLX after Weak 2Q13Zacks(Wed, May 29)
- First Large-Scale Population-Based Study in the U.S. Shows Hologic's 3D Mammography (Breast Tomosynthesis) Significantly Reduces Recall Rates While Simultaneously Improving Cancer DetectionPR Newswire(Thu, May 23)
- Hologic Receives FDA Approval for a New Low-dose 3D Mammography (Breast Tomosynthesis) Solution for Breast Cancer ScreeningPR Newswire(Tue, May 21)
- HOLX July Options Begin Tradingat Forbes(Mon, May 20)
- JPMorgan: S&P at 1,715at Barrons.com(Fri, May 17)
Press Releases
- Quest Diagnostics and Hologic Form Strategic Alliance to Improve Women's HealthPR Newswire(Thu, Jun 6)
- First Large-Scale Population-Based Study in the U.S. Shows Hologic's 3D Mammography (Breast Tomosynthesis) Significantly Reduces Recall Rates While Simultaneously Improving Cancer DetectionPR Newswire(Thu, May 23)
- Hologic Receives FDA Approval for a New Low-dose 3D Mammography (Breast Tomosynthesis) Solution for Breast Cancer ScreeningPR Newswire(Tue, May 21)
Reports
- HOLX: Due Diligence Review: Forensic Earnings and ValuationNew Constructs, LLC(Jun 19)
- Trading Report for (HOLX). A detailed report, including free correlated market...Stock Traders Daily(Jun 19)
- ValuEngine Industry Report for Medical InstrumentsValuEngine, Inc.(Jun 19)